A5029038251- Ovarian cancer diagnosis and treatment
- Hematopoietic Stem Cell Transplantation
- Estrogen and related hormone effects
- Cancer Research and Treatments
- Erythropoietin and Anemia Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Metal complexes synthesis and properties
- COVID-19 and healthcare impacts
- Neutropenia and Cancer Infections
- Cervical Cancer and HPV Research
- Endometrial and Cervical Cancer Treatments
- Healthcare cost, quality, practices
- Antibiotics Pharmacokinetics and Efficacy
- Protease and Inhibitor Mechanisms
- Polyomavirus and related diseases
- Chemotherapy-induced cardiotoxicity and mitigation
- Ferrocene Chemistry and Applications
- Chemotherapy-induced organ toxicity mitigation
- Mesenchymal stem cell research
- Chemical Reactions and Isotopes
- Surgical Sutures and Adhesives
- Prostate Cancer Treatment and Research
Università Cattolica del Sacro Cuore
1990-2022
Carlo Forlanini Hospital
2020
Sapienza University of Rome
2001
University of the Sacred Heart
2001
Casa Sollievo della Sofferenza
1999
Istituti di Ricovero e Cura a Carattere Scientifico
1999
University of Trieste
1994-1995
Ospedale Maggiore
1973
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
1973
PURPOSE The aim of the study was to investigate role squamous cell carcinoma antigen (SCC) in management patients with locally advanced cervical cancer treated by neoadjuvant chemotherapy and radical surgery. PATIENTS AND METHODS SCC assay performed a radioimmunoassay kit series 102 cancer. values 2.5, 5, 7 ng/mL were used define positivity. chi 2 Fisher's exact test stepwise logistic regression evaluate distribution marker values. Analysis survival using Kaplan Meier Cox multivariate...
In Brief The objective of this study was to assess the reconstructive options after radical, extensive vulvectomy; relate them tumor characteristics; and select a choice flaps able correct every remaining defect. This is retrospective review 4-year experience with 31 in 20 consecutive vulvar reconstructions. Three presented nonsignificant delayed healing at their tips 3 other developed major breakdown related an infection or error flap planning. According authors, size defect main issue that...
PURPOSE AND METHODS: The ability of granulocyte colony-stimulating factor (G-CSF) plus erythropoietin (EPO) treatment was compared in a randomized fashion with that G-CSF alone promoting hematologic recovery and peripheral-blood progenitor-cell (PBPC) mobilization previously untreated patients advanced ovarian cancer who underwent their first course epirubicin, paclitaxel, cisplatin (ETP) chemotherapy during phase II study intensive outpatient ETP followed by high-dose carboplatin,...
Objective:
We investigated the feasibility of a programme autologous blood stem cell (ABSC) harvesting and transplantation in 13 patients with advanced ovarian cancer, previously untreated by chemotherapy or radiotherapy entering phase II study high‐dose cisplatin, etoposide carboplatin haematopoietic rescue. Prior to treatment all underwent two courses cisplatin cyclophosphamide. An 8‐fold increase peripheral colony forming unit granulocytic‐macrophage (CFU‐GM) was observed during recovery from...
The treatment of recurrent or progressive ovarian cancer has limited therapeutic potential. clinical outcome second-line therapy largely depends on the potential chemo-sensitivity tumor expressed during up-front chemotherapy, as well treatment-free interval from last course cytotoxic therapy. However, identification agents such tamoxifen (TAM) at nontoxic doses, able to act synergistically with standard may be useful overcome resistance. Fifty patients following platinum (P)-based...
In order to investigate the effects of erythropoietin (EPO) plus granulocyte colony‐stimulating factor (G‐CSF) administration after peripheral blood progenitor cell transplantation (PBPCT) we performed a phase I/II study in patients with high‐risk cancer. 15 consecutive were treated recombinant human G‐CSF (rhG‐CSF) at dose 5 μg/kg subcutaneously (s.c.) every 24 h until day +12 and EPO (rhEPO) 150 IU/kg s.c. 48 +11 following PBPCT. Their haemopoietic recovery was compared that obtained eight...
The combinational treatment between the selective antimetastatic agent, sodium-trans-rutheniumtetrachloridedimethylsulfoxideimidazole, Na[trans-RuCl(4)(DMSO)Im], and cytotoxic drug 5-fluorouracil (5-FU) on primary tumor growth survival time of experimental tumors results in an effect significantly greater than that each single agent used alone either with solid metastasizing MCa mammary carcinoma CBA mouse or lymphocytic leukemia P388 its platinum resistant P388/DDP subline. Thus inorganic...
BACKGROUND: Peripheral blood progenitor cell (PBPC) transplantation (PBPCT) combined with post‐PBPCT administration of myelopoietic growth factors is a valid therapeutic intervention to rapidly restore hematopoiesis after the delivery intensive, myeloablative cancer chemotherapy. On other hand, best factor regimen potentiate PBPC‐mediated immunohematopoietic recovery has yet be determined. STUDY DESIGN AND METHODS: In randomized evaluation, effects produced by G–CSF and GM–CSF on...
Abstract Objectives: Reconstitution of hematopoiesis by means peripheral blood stem cells is a valid alternative to autologous bone marrow transplantation. The aim this investigation was increase the efficiency collection circulating progenitor and obtain purer product for transplant. Methods: We carried out leukapheresis procedures with Fresenius AS 104 cell separator, using two different protocols, previously used PBSC‐LYM new mononuclear program. Results: Both programs were highly...
Fourteen patients with advanced ovarian carcinoma (FIGO stages III–IV) resistant to cisplatin were submitted an alternating regimen doxorubicin (A), cyclophosphamide (C), bleomycin (B) and mitomycin C (M). All had measurable disease on entry into the study. No responses observed while 3 patients, previously showing no change in cisplatin, stabilization lasting 3, 4 6 months, respectively. but 1 patient died a median survival from start of ACBM therapy 7 months (range 6–11). ACBM-induced...
A new biological response modifier, L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine hydrochloride (AdTP), recently synthesized and characterized for antitumor, antiviral immunomodulating properties was studied in comparison to the peptidoglycan monomer (PGM) isolated from Brevibacterium divaricatum test effects of their use concomitant that anticancer cytotoxic drugs such as cyclophosphamide, 5-fluorouracil (5-FU), cisplatin 4-(3,3-dimethyl-1-triazeno)-5-carboxamide (dacarbazine). The...
The treatment of recurrent or progressive ovarian cancer has limited therapeutic potential. clinical outcome second-line therapy largely depends on the potential chemo-sensitivity tumor expressed during up-front chemotherapy, as well treatment-free interval from last course cytotoxic therapy. However, identification agents such tamoxifen (TAM) at nontoxic doses, able to act synergistically with standard may be useful overcome resistance. Fifty patients following platinum (P)-based...
<h3>Objective</h3> Several attempts are done in order to control COVID-19 and promote a fair allocation of resources during the outbreak. The Italian society obstetrics gynecologist (SIGO), Multicenter Trials Ovarian cancer gynecologic malignancies (MITO) promoting research activities field oncology on national basis, even era COVID-19. <h3>Methods</h3> SIGO MITO group promoted survey aiming evaluate impact clinical activity oncologists implementation containment measures diffusion....